English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Heart failure (HF) is frequently associated with renal dys-function. Thus, therapeutic strategies in HF should notadversely affect renal function. Cyclic guanosine mono-phosphate cGMP) is a second messenger generated byboth soluble and particulate guanylate cyclase (sGC andpGC, respectively). We hypothesized that cGMP activa-tion of sGC, pGC, or both (by BAY 58-2667, a novel directnitric oxide-independent sGC activator [1], and/or thepGC stimulator B-type natriuretic peptide (BNP)) wouldhave beneficial renal actions in experimental heart failure.

Co-activation of soluble and particulate guanylate cyclase by BAY 58-2667 and BNP enhances cardiorenal function in experimental heart failure